This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharma: Guessing Q3 Fusilev Sales

HENDERSON, Nev. ( TheStreet) --September sales of the Spectrum Pharmaceuticals' (SPPI - Get Report) colon cancer drug Fusilev totaled $31.5 million in September, according to an estimate compiled by healthcare research firm Wolters Kluwer Wednesday.

For the three months that make up the third quarter, Fusilev estimated sales totaled $99 million. July sales were $31.8 million, August sales $35.4 million, according to Wolters Kluwer.

How accurately the Fusilev sales estimates track actual sales reported by Spectrum is a guessing game. In the second quarter, Spectrum reported Fusilev sales of $56.6 million, short of the $97 million suggested by the Wolters Kluwer monthly sales data.

Wolters Kluwer tracks gross sales of Fusilev while Spectrum reports net sales that subtract discounts, rebates and other financial incentives to doctors. As previously reported, Spectrum increased Fusilev discounting in the June quarter, which lowered the effective net selling price of Fusilev.

If the same rough gross-to-net discounting trend continued in the third quarter, Spectrum could report slightly higher Fusilev sales of around $57 million.

With so few analysts covering Spectrum, generating consensus estimates is difficult. Roth Capital Partners' Joe Pantginis lowered his third-quarter Fusilev sales estimate to $50.1 million from $58.2 million. RBC Capital's Adnan Butt is forecasting $59.4 million in Fusilev sales for the quarter.

Fusilev sales comprised 86% of Spectrum's second-quarter revenue so how well the drug performs is vitally important to the company's future growth. Spectrum continues to benefit from supply shortages of leucovorin, a cheaper, generic equivalent to Fusilev.

Spectrum shares were up 1% to $11.36 in early Wednesday trading. The stock is down 20% for the year despite a strong returns for the biotech sector, generally.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
SPPI $6.10 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs